Clinical trials: Intermittent Explosive Disorder
Intermittent Explosive Disorder
Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder
This study is designed to explore the safety and tolerability, and to compare the activity of SRX246 against placebo, in adults with Intermittent Explosive Disorder (IED).
- Trial name
- AVN009 (NCT02055638)
- Testing
- SRX246
- Where
- 7 sites in United States
- Volunteers
- 97 people
- Sponsor
- Azevan Pharmaceuticals
Intermittent Explosive Disorder
A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder
This study will compare the medications fluoxetine (Prozac®) and divalproex (Depakote®) for the treatment of aggressive behavior in individuals with Intermittent Explosive Disorder (IED).
- Trial name
- NCT00078754
- Testing
- Fluoxetine, Divalproex
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Chicago
Intermittent Explosive Disorder, Childhood Aggression
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
Children with explosive aggression are often rejected by their peers, placed in special classroom, and contribute to family discord. When psychotherapy and family therapy is unsuccessful, medications are often used.
- Conditions
- Intermittent Explosive Disorder, Childhood Aggression, Oppositional Defiant Disorder, Attention Deficit Disorder
- Trial name
- NCT02048241
- Testing
- Parent Management Training, Intuniv
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- New York State Psychiatric Institute
Intermittent Explosive Disorder
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate AVP-786 for the treatment of Intermittent Explosive Disorder (IED).
- Trial name
- NCT03420222
- Testing
- AVP-786
- Where
- 9 sites in United States
- Volunteers
- 10 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.